Expired Canadian patentCanada
Cd45rb binding compounds for the prevention of transplant rejection
CA 2218289 C · Owner: Alimmune, L.L.C. · Inventors: Lazarovits, Andrew I.; Poppema, Sibrandes
Overview
Drawings and full text
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
Compounds and methods are described for the differential augmentation of tyrosine phosphorylation of phospholipase C-.gamma.1 for the prevention or , reversal of transplant rejection as well as therapy for autoimmune diseases.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed April 18, 1996 and granted February 5, 2002. A Canadian patent filed from October 1, 1989 lasts 20 years from filing, so its term ended April 18, 2016.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by April 18, 2018.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
FiledApril 18, 1996
GrantedFebruary 5, 2002
Term endedApril 18, 2016
Patent numberCA 2218289 C
Classification (IPC)A61K39/39 +2 more
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.